Severe Neuro-COVID is associated with peripheral immune signatures, autoimmunity and neurodegeneration: a prospective cross-sectional study.

Autor:	Etter MM; Brain Tumor Immunotherapy Lab, Department of Biomedicine, University of Basel, Basel, Switzerland., Martins TA; Brain Tumor Immunotherapy Lab, Department of Biomedicine, University of Basel, Basel, Switzerland., Kulsvehagen L; Departments of Neurology, Biomedicine and Clinical Research, & Research Center for Neuroimmunology and Neuroscience Basel, University Hospital Basel, University of Basel, Basel, Switzerland., Pössnecker E; Departments of Neurology, Biomedicine and Clinical Research, & Research Center for Neuroimmunology and Neuroscience Basel, University Hospital Basel, University of Basel, Basel, Switzerland., Duchemin W; sciCORE Center for Scientific Computing, University of Basel, Basel, Switzerland., Hogan S; Brain Tumor Immunotherapy Lab, Department of Biomedicine, University of Basel, Basel, Switzerland., Sanabria-Diaz G; Translational Imaging in Neurology (ThINK) Basel, Department of Medicine and Biomedical Engineering, University Hospital Basel, University of Basel, Basel, Switzerland., Müller J; Translational Imaging in Neurology (ThINK) Basel, Department of Medicine and Biomedical Engineering, University Hospital Basel, University of Basel, Basel, Switzerland.; Department of Neurology, University Hospital Basel, Basel, Switzerland., Chiappini A; Department of Neurosurgery, University Hospital Basel, Basel, Switzerland., Rychen J; Department of Neurosurgery, University Hospital Basel, Basel, Switzerland., Eberhard N; Department of Neurosurgery, University Hospital Basel, Basel, Switzerland., Guzman R; Department of Neurosurgery, University Hospital Basel, Basel, Switzerland.; Department of Surgery, University Hospital Basel, Spitalstrasse 21, Basel, Switzerland., Mariani L; Department of Neurosurgery, University Hospital Basel, Basel, Switzerland.; Department of Surgery, University Hospital Basel, Spitalstrasse 21, Basel, Switzerland., Melie-Garcia L; Translational Imaging in Neurology (ThINK) Basel, Department of Medicine and Biomedical Engineering, University Hospital Basel, University of Basel, Basel, Switzerland.; Department of Neurology, University Hospital Basel, Basel, Switzerland., Keller E; Neurosurgical Intensive Care Unit, Department of Neurosurgery and Institute of Intensive Care Medicine, University Hospital Zurich, Zurich, Switzerland., Jelcic I; Neuroimmunology and Multiple Sclerosis Research Section, Department of Neurology, University Hospital Zurich, Zurich, Switzerland., Pargger H; Department of Intensive Care Medicine, University Hospital Basel, Basel, Switzerland., Siegemund M; Department of Intensive Care Medicine, University Hospital Basel, Basel, Switzerland., Kuhle J; Department of Neurology, University Hospital Basel, Basel, Switzerland., Oechtering J; Translational Imaging in Neurology (ThINK) Basel, Department of Medicine and Biomedical Engineering, University Hospital Basel, University of Basel, Basel, Switzerland.; Department of Neurology, University Hospital Basel, Basel, Switzerland., Eich C; Brain Tumor Immunotherapy Lab, Department of Biomedicine, University of Basel, Basel, Switzerland., Tzankov A; Department of Pathology, Institute of Medical Genetics & Pathology, University Hospital Basel, University of Basel, Basel, Switzerland., Matter MS; Department of Pathology, Institute of Medical Genetics & Pathology, University Hospital Basel, University of Basel, Basel, Switzerland., Uzun S; Department of Pathology, Institute of Medical Genetics & Pathology, University Hospital Basel, University of Basel, Basel, Switzerland., Yaldizli Ö; Translational Imaging in Neurology (ThINK) Basel, Department of Medicine and Biomedical Engineering, University Hospital Basel, University of Basel, Basel, Switzerland., Lieb JM; Department of Neuroradiology, Clinic for Radiology & Nuclear Medicine, University Hospital Basel, Basel, Switzerland., Psychogios MN; Department of Neuroradiology, Clinic for Radiology & Nuclear Medicine, University Hospital Basel, Basel, Switzerland., Leuzinger K; Division of Medical Immunology, Laboratory Medicine, University Hospital Basel, Basel, Switzerland.; Clinical Virology, University Hospital Basel, Basel, Switzerland., Hirsch HH; Clinical Virology, University Hospital Basel, Basel, Switzerland.; Transplantation & Clinical Virology, Department of Biomedicine, University of Basel, Basel, Switzerland.; Infectious Diseases & Hospital Epidemiology, University Hospital Basel, Basel, Switzerland., Granziera C; Translational Imaging in Neurology (ThINK) Basel, Department of Medicine and Biomedical Engineering, University Hospital Basel, University of Basel, Basel, Switzerland.; Department of Neurology, University Hospital Basel, Basel, Switzerland., Pröbstel AK; Departments of Neurology, Biomedicine and Clinical Research, & Research Center for Neuroimmunology and Neuroscience Basel, University Hospital Basel, University of Basel, Basel, Switzerland., Hutter G; Brain Tumor Immunotherapy Lab, Department of Biomedicine, University of Basel, Basel, Switzerland. gregor.hutter@usb.ch.; Department of Neurosurgery, University Hospital Basel, Basel, Switzerland. gregor.hutter@usb.ch.; Department of Surgery, University Hospital Basel, Spitalstrasse 21, Basel, Switzerland. gregor.hutter@usb.ch.
Jazyk:	angličtina
Zdroj:	Nature communications [Nat Commun] 2022 Nov 09; Vol. 13 (1), pp. 6777. Date of Electronic Publication: 2022 Nov 09.
DOI:	10.1038/s41467-022-34068-0
Abstrakt:	Growing evidence links COVID-19 with acute and long-term neurological dysfunction. However, the pathophysiological mechanisms resulting in central nervous system involvement remain unclear, posing both diagnostic and therapeutic challenges. Here we show outcomes of a cross-sectional clinical study (NCT04472013) including clinical and imaging data and corresponding multidimensional characterization of immune mediators in the cerebrospinal fluid (CSF) and plasma of patients belonging to different Neuro-COVID severity classes. The most prominent signs of severe Neuro-COVID are blood-brain barrier (BBB) impairment, elevated microglia activation markers and a polyclonal B cell response targeting self-antigens and non-self-antigens. COVID-19 patients show decreased regional brain volumes associating with specific CSF parameters, however, COVID-19 patients characterized by plasma cytokine storm are presenting with a non-inflammatory CSF profile. Post-acute COVID-19 syndrome strongly associates with a distinctive set of CSF and plasma mediators. Collectively, we identify several potentially actionable targets to prevent or intervene with the neurological consequences of SARS-CoV-2 infection. (© 2022. The Author(s).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Full text from SpringerLink